The FDA approved a label expansion for Novo Nordisk’s obesity drug Wegovy, highlighting its heart benefits. A large trial showed a 20% reduction in cardiovascular problems for overweight or obese individuals with heart disease. Novo Nordisk is also addressing counterfeit versions of its diabetes drug Ozempic in multiple countries, with reports of patient harm. The increasing demand for weight loss drugs has led to concerns about unregulated and counterfeit medicines. Patients in several countries experienced harm after taking fake Ozempic. Overall, the week starts with the familiar routine of work, online meetings, and deadlines, but a cup of coffee can help kickstart the day.
Source link
We’re reading about Wegovy approved for heart risks, an ALS drug
